Friends who follow the medical sector know that since the beginning of the year, the US Biosafety Act (that is, the bill to restrict Yao Ming Kant and Chinese biotechnology companies) has had a severe impact on the share price of Yao Ming system. Today (May 13) AH Pharmaceutical stocks collectively jumped high, what is the reason?Dragonbonusbaccarat? Yes, it's this bill again.
On May 10, local time, Congress issued a revised version of the Biosafety Act, which extends immunity from existing contracts / products until January 1, 2032 (that is, requiring US companies to end their cooperation with these companies by 2032). Some people in the industry believe that 8 years is enough for the relevant companies to respond, and the landing of this greatest uncertainty may have a positive impact on the relevant companies.
However, some market participants believe that although there is a respite, it also leads to a more practical bill, and the pressure on the long-term development of the domestic pharmaceutical industry may increase.
The divergence of views intensified during the session, and the medicine department dived. By the end of the day, A-share Pharmaceutical Kant closed up 2.Dragonbonusbaccarat.99%, the whole-day amplitude is as high as 6.44%.
From the overall market of the medical sector, component stocks fell more than up less, outnumbered, so that medical ETF (512170) finally closed down slightly. However, the afternoon premium widened in the afternoon, and the closing premium rate still reached 0.26%, indicating that the buying funds were relatively strong and the bulls may start to sell.
For a long time, the medical sector has a short-term market in the near future. Last week (May 6-10), the medical ETF (512170) weekly line received three Lianyang. The underlying index, CSM, rose 10.57 per cent in the past three weeks, significantly surpassing the performance of the Shanghai Index (2.91 per cent) and Shanghai and Shenzhen 300 (3.52 per cent) over the same period.
In "China Merchants Bank International China Pharmaceutical: industry support Policy is expected to land, performance recovery is expected", China Bank International said that the pharmaceutical industry may continue to rebound, mainly because: 1) domestic policies are expected to improve, medical equipment renewal policies effectively stimulate procurement demand, health insurance payment environment for innovative products is improved, and hospital medical demand is expected to continue to recover after the normalization of anti-corruption. 2) go out to sea to provide additional growth momentum, authorized trading of innovative drugs is expected to continue to land, innovative medical devices to expand overseas markets; 3) GLP-1, ADC and other long-term investment opportunities; 4) plate valuation attracts, the dynamic price-to-earnings ratio of most leading stocks is lower than the historical average of 1 standard deviation, and the dividend yield of some stocks is attracted.
What needs to be reminded is that the medical and medical sector has been adjusted for a long time, and the recovery of the short-term market does not represent a complete reversal of the market. Investors who pay attention to the medical and medical sector must invest rationally according to their own financial situation and risk bearing ability. pay close attention to risk management, or can fall in batches, do not blind Suha.
The picture comes from iFinD, Shanghai and Shenzhen Stock Exchange and Warburg Fund. Risk Tip: medical ETF (512170) and its linked funds passively track the CSI Medical Index, which is based on December 31, 2004 and released on October 31, 2014. In this paper, the index stocks are only displayed, and the individual stocks are not described as any form of investment advice, nor do they represent the position information and trading trends of any fund under the manager. The sub-annual performance of the China Securities Medical Index from 2019 to 2023 is 48.67%, 79.67%,-14.71%,-25.1% and-24.25% respectively. The composition of the underlying index stocks is timely adjusted in accordance with the rules governing the compilation of the index, and its historical performance does not predict the future performance of the index. The risk grades of the fund and its linked funds assessed by the fund manager are R3-medium risk and R4-medium-high risk respectively, which are suitable for balanced (C3), active (C4) and above investors, respectively. Any information that appears in this article (including but not limited to individual stocks, comments, forecasts, charts, indicators, theories, any form of expression, etc.) is for reference only and the investor is responsible for any discretionary investment behavior. In addition, any point of view, analysis and forecast in this article does not constitute any form of investment advice to the reader, nor is it liable for direct or indirect losses arising from the use of the contents of this article. Fund investment is risky, the past performance of the fund does not represent its future performance, and the performance of other funds managed by fund managers does not constitute a guarantee of fund performance, so fund investment should be cautious.